Document Actions
NCI Advisors Criticize Plan To Fund R01s With Amgen, J&J Money
From The Cancer Letter, June 27, 2008:
A research program shot down by NCI scientific advisors earlier this week was unlike any other:The institute proposed using $5 million in pharmaceutical industry money to pay for up to three R01 grants to study the tumor promotion potential of erythropoiesis-stimulating agents.
The money would be contributed by the sponsors of the controversial agents—Amgen Inc. and Johnson & Johnson—and floated through the Foundation for the National Institutes of Health, a non-profit created by Congress to raise private funds to help support biomedical research.
Click on The Cancer Letter Archive at left to download the June 27 issue (subscription required). Related documents for this story posted under Special Reports.
_____
tags:
Friday, June 27, 2008
in
NCI
| research funding
| Permalink |
Comments (0)
trackback URL: http://www.cancerletter.com/tcl-blog/copy54_of_whats-going-on-with-nih/sbtrackback
Forgot your password?